Department of Internal Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.I.N.).
Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, MA (E.W.G., T.R.-C., M.S., P.Q., S.M., L.M.F., R.S., J.E.H., A.R.G.).
Circ Heart Fail. 2023 Jul;16(7):e010152. doi: 10.1161/CIRCHEARTFAILURE.122.010152. Epub 2023 Jun 22.
Acute myocarditis can result in severe hemodynamic compromise requiring venoarterial extracorporeal membrane oxygenation (VA-ECMO). Outcomes and factors associated with mortality among myocarditis patients are not well described in the modern ECMO era.
We queried the Extracorporeal Life Support Organization registry from 2011 to 2020 for adults with suspected acute myocarditis undergoing peripheral VA-ECMO support. The primary outcome was in-hospital mortality and was compared to all-comers receiving VA-ECMO in the registry over the same period. Secondary outcomes were rates of bridging to advanced therapies and ECMO complications. We used multivariable logistic regression to examine factors associated with in-hospital mortality.
Among 850 patients with suspected acute myocarditis receiving peripheral VA-ECMO, the mean age was 41 years, 52% were men, 39% Asian race, and 14.8% underwent extracorporeal cardiopulmonary resuscitation. During the study period, in-hospital mortality steadily declined and was 58.3% for all all-comers receiving VA-ECMO compared with 34.9% for patients with myocarditis (<0.001). After multivariable modeling, risk factors for mortality were earlier year of support, older age, higher weight, Asian race, need for extracorporeal cardiopulmonary resuscitation, sepsis, and lower mean arterial pressure and pH prior to ECMO initiation. ECMO complications including bleeding, limb ischemia, infections and ischemic stroke were more common among nonsurvivors and significantly declined during the study period.
Compared with all-comers supported with VA-ECMO, in-hospital mortality for patients with acute myocarditis is significantly lower, with nearly two-thirds of patients surviving to discharge. Major modifiable risk factors for mortality were ongoing cardiopulmonary resuscitation requiring ECMO and markers of illness severity prior to ECMO.
急性心肌炎可导致严重的血液动力学障碍,需要进行静脉-动脉体外膜肺氧合(VA-ECMO)治疗。在现代 ECMO 时代,心肌炎患者的预后和与死亡率相关的因素尚未得到很好的描述。
我们从 2011 年至 2020 年,在外周 VA-ECMO 支持下,对疑似急性心肌炎的成年患者进行了体外生命支持组织登记处查询。主要结果是住院死亡率,并与同期登记处接受 VA-ECMO 的所有患者进行了比较。次要结果是桥接高级治疗和 ECMO 并发症的发生率。我们使用多变量逻辑回归分析来研究与住院死亡率相关的因素。
在 850 例接受外周 VA-ECMO 治疗的疑似急性心肌炎患者中,平均年龄为 41 岁,52%为男性,39%为亚洲人种,14.8%接受了体外心肺复苏。在研究期间,所有接受 VA-ECMO 治疗的患者中,住院死亡率稳步下降,为 58.3%,而心肌炎患者为 34.9%(<0.001)。经过多变量建模,死亡率的危险因素包括支持年限较早、年龄较大、体重较高、亚洲人种、需要体外心肺复苏、脓毒症以及 ECMO 启动前的平均动脉压和 pH 值较低。与幸存者相比,非幸存者的 ECMO 并发症(包括出血、肢体缺血、感染和缺血性中风)更为常见,并且在研究期间显著减少。
与接受 VA-ECMO 治疗的所有患者相比,急性心肌炎患者的住院死亡率明显较低,近三分之二的患者存活至出院。死亡率的主要可改变危险因素是需要 ECMO 的持续心肺复苏和 ECMO 前疾病严重程度的标志物。